Craig Levinson

About Craig Levinson

Craig Levinson is a life sciences sales leader with more than 20 years of experience supporting pharmaceutical and bioprocessing organizations across North America. His career includes technical application roles, strategic account management, and regional sales leadership. He has led teams, negotiated master supply agreements, and managed revenue responsibility exceeding $140 million. Craig has worked with global pharmaceutical companies, emerging biotechs, academic institutions, and contract manufacturers, helping customers adopt technologies critical to commercial manufacturing.

Education and Academic Background

Craig Levinson completed his undergraduate education at Knox College in Galesburg, Illinois, earning a Bachelor of Arts in History in 1994. Following his graduation from Knox College, Craig pursued a second undergraduate degree to advance his scientific training. He enrolled at the University of New Mexico in Albuquerque, where he completed a Bachelor of Science in Biochemistry in 2000.

Entry into the Life Sciences Industry at Packard Bioscience

Craig Levinson of Carmel, Indiana, began his professional career in the life sciences industry in 2000 at Packard Bioscience, where he joined as a Customer Application Engineer. His responsibilities focused on training customers after the installation of liquid-handling instrumentation and multimode microplate readers.

During this period, Craig worked with customers engaged in drug discovery and regulated laboratory operations. These environments included contract research organizations, core laboratories, and GLP and GMP facilities.

Transition into Technical Sales at Waters Corporation

In 2002, Craig Levinson joined Waters Corporation as a Technical Sales Specialist. He managed a three-state territory that included major pharmaceutical and industrial customers. His accounts included Eli Lilly, Pfizer, Pharmacia, Dow AgroSciences, and Procter & Gamble.

Craig delivered technical presentations to scientists working in quality assurance, quality control, and process development. He was responsible for increasing customer engagement and expanding market share within his territory.

Business Development and Market Expansion at Sigma-Aldrich SAFC

Craig joined Sigma-Aldrich SAFC in 2004 as a Business Development Manager, marking a significant step forward in his commercial career. In this role, he served as a sales specialist focused on cell culture media and critical raw materials used in biopharmaceutical manufacturing.

From 2006 through 2010, Craig managed multiple territories, including emerging biotechnology companies and large pharmaceutical firms. Between 2010 and 2014, Craig managed the animal health business across North America. This role expanded his scope of responsibility and required coordination across regions and customer segments.

Throughout his time at Sigma-Aldrich, Craig Levinson led cross-functional teams composed of internal specialists and customer-facing experts. He successfully designed platform media and critical raw materials into several major accounts, including Eli Lilly, Alexion, Novavax, Lonza, Elanco, BIVI, and Merck Animal Health.

Account Management at Cytiva and GE Healthcare Life Sciences

In 2014, Craig joined Cytiva (formerly GE Healthcare Life Sciences) as an Account Manager. He was responsible for a two-state territory that included pharmaceutical companies, emerging biotechnology firms, and contract manufacturing organizations.

His accounts included Eli Lilly, Catalent, Genezen, IBRI, Elanco, Beckman Coulter, Exelead, Purdue University, Indiana University, and KP Pharmaceuticals. Between 2019 and 2020, Craig successfully grew emerging biotechnology accounts in his territory, closing more than $5 million in new business.

Craig partnered with the general manager of service to develop a strategy to regain service contract business at Eli Lilly, valued at $1 million. He also collaborated with local teams to penetrate cell and gene therapy accounts. This collaboration led to the closure of a $2 million integrated solutions opportunity at Genezen, with potential for further expansion.

Strategic Account Leadership at Cytiva

Craig Levinson of Carmel, Indiana, later transitioned to a Strategic Account Manager role at Cytiva, assuming responsibility for major global accounts, including Eli Lilly, Takeda, and Fujifilm Diosynth, within his assigned territory.

One of his most significant accomplishments during this period was the successful execution of a global master supply agreement with Eli Lilly. This agreement had been under negotiation for five years before his involvement and carried an estimated lifetime value of approximately $200 million.

At Takeda’s Brooklyn Park, Minnesota site, Craig supported the design-in of multiple technologies, including lab-scale AKTA systems, mixers, and Axichrom columns. These technologies supported two commercial manufacturing processes with a combined value exceeding $10 million.

Craig also played a key role in delivering innovative solutions at Eli Lilly. He supported the design-in of AKTA PCC systems and PrismA resin, positioning Eli Lilly as one of the earliest adopters of PrismA. This resin is now used across multiple late-phase processes, with cumulative sales exceeding $50 million.

Regional Sales Leadership at Repligen

In 2022, Craig Levinson of Carmel, Indiana, joined Repligen as West Coast Regional Manager. In this role, he managed a team of nine bioprocess account managers who sold the complete Repligen product portfolio across the region.

In 2023, Craig was responsible for $140 million in revenue. In his first year at Repligen, he achieved 120% of the 2022 plan, demonstrating his ability to adapt to a new organization.

Interest in Health, Wellness, and Longevity Science

Alongside his professional career in the life sciences, Craig Levinson of Carmel, Indiana, has developed a personal interest in health and wellness based on scientific evidence. His interest is informed by decades of working within data-driven environments where outcomes depend on measurable inputs.

Craig has developed expertise in nicotinamide adenine dinucleotide supplementation and other longevity-focused protocols. His approach emphasizes understanding underlying biological mechanisms and applying interventions consistently over time.